Newmed Energy-limited Partnership, IL0004750209

NewMed Energy terminates gas engagement: NewMed Energy stock holds 45.30 percent

Published on 10/16/2026 at 10:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NewMed terminated the gas-sale engagement on October 7, 2026. NewMed Energy stock ties to 45.30 percent of Leviathan and Q2 sales rose 52.90 percent.

Gas agreement and operating figures

NewMed terminated its gas-sale engagement on October 7, 2026.
Second-quarter gas and condensate sales rose 52.90 percent to USD 293.20 million.
First-half net profit fell 79.70 percent to USD 117.90 million.
NewMed holds a 45.30 percent working interest in Leviathan.

Newmed Energy-limited Partnership, IL0004750209, Illustration mit AI erstellt.

NewMed Energy-limited Partnership (ISIN IL0004750209) terminated its engagement in a natural-gas sales agreement on October 7, 2026, according to the company's investor-relations page. The move keeps the partnership at the center of a dispute over fuel supply and project financing rather than adding a new production asset.

Why the gas agreement matters

The commercial issue is material because NewMed participates in the Leviathan field, where it holds a 45.30 percent working interest, as stated on the company's investor-relations page. Deep TASE reported on September 27, 2026, that the canceled agreement covered gas supply for Dalia Energy's Ashkel Avshal expansion and that the project had drawn NIS 4,500.00 million in construction debt.

The operating picture is mixed. Gas and condensate sales rose 52.90 percent to USD 293.20 million in the second quarter of 2026, while consolidated net profit fell 79.70 percent to USD 117.90 million in the first half of 2026, according to Deep TASE. The contrast puts volume growth beside higher execution and financing pressure.

Three dates shape the dispute

On August 13, 2026, NewMed published its second-quarter and first-half report, with second-quarter gas and condensate sales at USD 293.20 million, as listed by MarketScreener. On September 27, 2026, Deep TASE described the cancellation dispute and cited a USD 500.00 million credit facility for Leviathan expansion. On October 7, 2026, the investor-relations page listed the termination of the engagement in the natural-gas sale agreement.

What comes next for NewMed

The next scheduled reporting date is November 12, 2026, according to TradingView. That report should clarify how the terminated agreement affects sales commitments, cash generation and the financing path for Leviathan.

For investors in Germany, the key distinction is between NewMed's gas growth and the disputed contract structure. The first-half profit decline gives the legal issue a financial dimension, while the 45.30 percent Leviathan interest preserves exposure to the partnership's core producing asset. On the TASE, the stock was trading at ILA 1,640.00 on October 16, 2026 at 10:52 a.m. IDT.